Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- PleoPharma, Inc.
- Study ID
- NCT07644052
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Cannabis Withdrawal
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- PP-01 — COMBINATION_PRODUCTCannabinoid-1 (CB1) partial agonist / GABAergic modulator
- Nabilone — DRUGCB1 partial agonist
- Placebo — DRUGPlacebo comparator
Study Details
This study is a randomized, double-blind, placebo and active-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe cannabis use disorder (CUD). Study participants will receive PP-01, nabilone, or placebo every day for 34 days. The total study duration will be approximately 78 days, including screening and a one-week inpatient stay. Following the initial inpatient portion of the study, participants will return to the clinic for six clinic visits and complete two telemedicine appointments. Participants will complete daily symptom diaries and other study-related questionnaires. Participants who complete the core study may be eligible to participate in a repeat dosing extension study if they meet required criteria.
Key Dates
- First listed
- Jun 12, 2026
- Start date
- Jun 17, 2026
- Status verified
- Jun 2026
- Primary completion
- Jul 31, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 420 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: PP-01Oral PP-01 tapered/titrated over 34 days
- Active Comparator: NabiloneOral Nabilone tapered/titrated over 34 days
- Placebo Comparator: PlaceboOral Placebo given daily for 34 days
Primary Outcome Measure
AUCs of the CSCW over Days 2 to 7, inclusive, comparing PP-01 vs Placebo [ Time Frame: Days to 2 to 7 ]
Central Contacts
- LBR Regulatory859-426-5035
- PleoPharma, Inc.610-937-2882
Locations (21)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Woodland International Research Group, LLC | Little Rock | Arkansas | 72211 | George Konis, MD (PRINCIPAL_INVESTIGATOR) |
| Woodland Research Northwest, LLC | Rogers | Arkansas | 72758 | Ryan Mahelona, MD (PRINCIPAL_INVESTIGATOR) |
| Yale Stress Center | New Haven | Connecticut | 06519 | Rajita Sinha, PhD (PRINCIPAL_INVESTIGATOR) |
| University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit | DeLand | Florida | 32720 | Andrea Marraffino, PhD (PRINCIPAL_INVESTIGATOR) |
| Research Centers of America | Hollywood | Florida | 33024 | Edwin A. Gomez, MD (PRINCIPAL_INVESTIGATOR) |
| Sandhill Research, LLC d/b/a Accel Research Sites - St. Pete - Largo Clinical Research Unit | Largo | Florida | 33777 | Rosario B. Hidalgo, MD (PRINCIPAL_INVESTIGATOR) |
| ForCare Clinical Research | Tampa | Florida | 33613 | Marlene P. Hart, MD (PRINCIPAL_INVESTIGATOR) |
| Neuroscience Research Institute | West Palm Beach | Florida | 33407 | Danesh Alam, MD (PRINCIPAL_INVESTIGATOR) |
| Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755 | Decatur | Georgia | 30030 | Marshall L. Nash, MD, FAHA, CPI, FAPCR (PRINCIPAL_INVESTIGATOR) |
| Evergreen Clinical Trials | Norcross | Georgia | 30092 | Dmitriy Pelishev, DO (PRINCIPAL_INVESTIGATOR) |
| CenExel iResearch, LLC | Savannah | Georgia | 31405 | Nancy E. Backus, MD (PRINCIPAL_INVESTIGATOR) |
| AMR Clinical | Lexington | Kentucky | 40509 | Mark S. Adams, MD (PRINCIPAL_INVESTIGATOR) |
| Maryland Psychiatric Research Center, University of Maryland School of Medicine | Baltimore | Maryland | 21228 | David A Gorelick, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Oasis Clinical Research | Las Vegas | Nevada | 89121 | Stephen Tam, MD (PRINCIPAL_INVESTIGATOR) |
| Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ | Marlton | New Jersey | 08053 | Elan A. Cohen, PhD (PRINCIPAL_INVESTIGATOR) |
| The Research Foundation for Mental Hygiene/ New York State Psychiatric Institute | New York | New York | 10032 | John Mariani, MD (PRINCIPAL_INVESTIGATOR) |
| Richmond Behavioral Associates | Staten Island | New York | 10314 | Romana Kulikova, MD (PRINCIPAL_INVESTIGATOR) |
| Neuro-Behavioral Clinical Research, Inc. | North Canton | Ohio | 44720 | Shishuka Malhotra, MD (PRINCIPAL_INVESTIGATOR) |
| Coastal Carolina Research Center, LLC | North Charleston | South Carolina | 29405 | Elizabeth Perkins, MD (PRINCIPAL_INVESTIGATOR) |
| AMR Clinical | Knoxville | Tennessee | 37920 | Jerry L. Punch, MD (PRINCIPAL_INVESTIGATOR) |
| Memorial Hermann Village | Houston | Texas | 77043 | Dominick Stevan D'Aunno, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Little Rock, AR
Related Studies
- Neuroimaging of Adolescent Cannabis Use TreatmentRecruiting · Indiana University · Indianapolis, Indiana